期刊
LANCET NEUROLOGY
卷 12, 期 1, 页码 84-91出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/S1474-4422(12)70295-8
关键词
-
资金
- Parkinson's UK
- EU
- NIHR
- MRC [G0600650, G0902100]
- British Heart Foundation [RG/08/014/24067] Funding Source: researchfish
- Medical Research Council [G0600650, MC_EX_G0902100, MR/L003120/1, MC_U105261167] Funding Source: researchfish
- National Institute for Health Research [NF-SI-0512-10165] Funding Source: researchfish
- The Cure Parkinsons Trust [CPT4] Funding Source: researchfish
- MRC [G0600650, MC_EX_G0902100, MC_U105261167, MR/L003120/1] Funding Source: UKRI
Clinical use of allografts of fetal ventral mesencephalic tissue as a treatment to replace dopaminergic neurons in patients with Parkinson's disease was first done more than 20 years ago. Since then, many patients have received transplants, with variable results. During this time, our knowledge of Parkinson's disease has changed and the nature and extent of problems associated with the disorder have been better defined. Our understanding on how best to implement this cell-replacement strategy for patients has grown, but gaining this insight has entailed critical reappraisal of data from transplant trials that have already been undertaken.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据